Verona Pharma plc Verona Pharma Plc : Holding(s) In Company
June 06 2017 - 7:30AM
UK Regulatory
TIDMVRP
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
1. Identity of the issuer or the underlying issuer Verona Pharma Plc
of existing shares to which voting rights are
attached: (ii)
2 Reason for the notification (please tick the appropriate
box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition of
shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar
economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify): Change to notifiable interest following X
share issue
3. Full name of person(s) subject to the Novo A/S
notification obligation: (iii)
4. Full name of shareholder(s)
(if different from 3.):(iv)
5. Date of the transaction and date on 19 May 2017
which the threshold is crossed or
reached: (v)
6. Date on which issuer notified: 5 June 2017
7. Threshold(s) that is/are crossed or Downward crossing of 12% threshold
reached: (vi, vii)
8. Notified details:
A: Voting rights attached to shares (viii, ix)
Class/type of
shares Situation previous
if possible using to the triggering
the ISIN CODE transaction Resulting situation after the triggering transaction
Number
Number of
of Voting Number Number of voting % of voting rights
Shares Rights of shares rights (x)
Indirect
Direct Direct (xi) (xii) Direct Indirect
Ordinary Shares (5p)
GB00B06GSH43 6,464,065 6,464,065 6,464,065 6,464,065 6.16%
ADSs
US9250501064 5,925,920 5,925,920 5,925,920 5,925,920 5.65%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Number of voting
rights that may be
acquired if the
Type of financial Expiration Exercise/ instrument is % of voting
instrument date (xiii) Conversion Period (xiv) exercised/ converted. rights
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
Resulting situation after the triggering transaction
Type of financial Exercise Expiration Exercise/ Conversion
instrument price date (xvii) period (xviii) Number of voting rights instrument refers to % of voting rights (xix, xx)
Nominal Delta
Total (A+B+C)
Number of voting rights Percentage of voting rights
12,389,985 11.81%
9. Chain of controlled undertakings through which
the voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease
to hold:
12. Date on which proxy holder will cease to hold
voting rights:
13. Additional information:
14. Contact name: Heather Ludvigsen
15. Contact telephone number: +45 3527 6576
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
June 06, 2017 07:30 ET (11:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
